Editas Medicine

+$0.12 (+0.60%) As of 7:04 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO
James C. Mullen
Employees
235
Headquarters
Cambridge, Massachusetts
Founded
2013

EDIT Key Statistics

Market cap
1.37B
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.86M
High today
$20.54
Low today
$19.63
Open price
$20.14
Volume
1.35M
52 Week high
$76.90
52 Week low
$19.63

EDIT News

Simply Wall StJan 14

What Kind Of Investors Own Most Of Editas Medicine, Inc.?

If you want to know who really controls Editas Medicine, Inc. (NASDAQ:EDIT), then you'll have to look at the makeup of its share registry. Insiders often own a

EDIT Earnings

-$1.00
-$0.63
-$0.25
$0.12
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Estimated
— per share
Actual
Expected Feb 24, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure